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10 Abstract The use of nanoemulsions in cosmetic products has
11 enlarged in the last decades because of several formulative
12 advantages (e.g. the improved self-life stability, better texture
13 properties). In addition, nanoemulsions seemed to improve the
14 penetration of active ingredients through the human skin,
15 comparing to conventional emulsion. In this contest, the risk
16 of a higher systemic exposure of consumer to active ingredi-
17 ents, due to the ability of nanoemulsion to enhance perme-
18 ation, results a critical attribute that should be evaluated for
19 assuring the consumer safety. The aim of this work was the
20 evaluation of how an oil-in-water (O/W) nanoemulsion can
21 influence the in vitro skin permeation profiles of two model
22 active ingredients with different polarity (i.e. caffeine and eth-
23 yl ximenynate). Preliminarily, since both selected molecules
24 impact on the physical stability of nanoemulsion, formulative
25 studies were carried out to identify the most stable formulation
26 to perform in vitro permeation studies. The overall results
27 demonstrated that nanoemulsions can significantly influence
28 the permeation profiles of molecules as a function of
29 their physicochemical properties. In particular, O/W
30 nanoemulsions can significantly improve the permeation pro-
31 files of apolar active ingredients in comparison to convention-
32 al emulsions, whereas no differences were observable for po-
33 lar molecules. Considering such findings, it is worth observ-
34 ing that there is room for reconsidering the risk assessment of
35 nanoemulsion-based cosmetic products.
36Keywords Nanoemulsion . Cosmetic . Risk assessment .
37Caffeine . Ethyl ximenynate
38Introduction
39Nanoemulsions are emulsions with uniform and extremely
40small droplets with size in the range of 20–200 nm [1, 2],
41whereas classical emulsions are characterized by a coarse
42droplet size which can reach 1 μm. Nanoemulsions appear
43transparent or translucent with a bluish Tyndall effect, which
44is light scattering phenomenon commonly observed in all col-
45loidal dispersions. In comparison to conventional emulsions,
46the nanosize droplets are more kinetic stable, resulting in a
47lower tendency of nanoemulsions to creaming, sedimentation,
48flocculation or coalescence [2, 3]. However, since they are
49non-equilibrium systems, nanoemulsions are usually obtained
50mechanically using both high-energy input (e.g. high-shear
51stirring, high-pressure homogenizers or ultrasound genera-
52tors) or low-energy emulsification methods, such as the phase
53inversion temperature (PIT) method [2, 4].
54Considering the technological advantages and the avail-
55ability of scalable manufacturing methods, the application of
56nanoemulsions in food, cosmetic and pharmaceutical fields
57has been increased in the last decades [5–8]. For example,
58nanoemulsions have been used in the manufacturing of sever-
59al cosmetic products intended to be applied on the skin, be-
60cause of the higher physical stability during shelf-life and the
61enhanced texture properties of the final product.
62Despite their nanosize dimension, this type of emulsions is
63not univocally considered as “nanomaterial” by a regulatory
64point of view [9]. Indeed, if they fulfil the nanomaterial defi-
65nition given by FDA [10], they are not according to the
66Regulatory Framework on cosmetic products currently
67enforced in the European Economic Area (EEA). Regulation
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68 (EC) No 1223/2009 defines a nanomaterial as “an insoluble or
69 biopersistant and intentionally manufactured material with
70 one or more external dimensions, or an internal structure, on
71 the scale from 1 to 100 nm”, excluding de facto all other
72 nanoscale soluble systems such as nanoemulsions [11].
73 Considering also that the regulatory requirements for cos-
74 metics containing nanomaterials are more stringent than for
75 conventional products [12], the different regulatory interpre-
76 tation between the Atlantic Ocean shores can significantly
77 influence the way in which manufacturers conduct the risk
78 assessment of nanoemulsion-based cosmetic products. Such
79 findings are more critical for cosmetic products intended to be
80 commercialized both in the USA and EEA.
81 From a toxicological point of view, nanoemulsion and con-
82 ventional emulsion are generally superimposable.
83 Nevertheless, risk concerning the skin permeation pattern of
84 active ingredients should be considered since it has been dem-
85 onstrated that nanoemulsion could enhance their permeation
86 profiles [5, 13]. In general, cosmetic ingredients can penetrate
87 the upper layer of human skin, but they must not permeate
88 in-depth through human skin. Therefore, the risk that their
89 permeation profile could be enhanced by using a
90 nanoemulsion should be considered as a critical attribute for
91 assuring the consumer safety.
92 The aim of this work was to evaluate how much the use of
93 an oil-in-water (O/WQ1 ) nanoemulsion in place of a convention-
94 al emulsion can influence the skin permeation of two model
95 active ingredients with different polarity (i.e. caffeine and eth-
96 yl ximenynate). Caffeine (CAF) was generally used in
97 anti-cellulite and anti-ageing products [14], whereas ethyl
98 ximenynate (EXM) is a microcirculation improver. Starting
99 from previous published studies [15] and preliminary results,
100 the oil phase composition and percentages of active ingredi-
101 ents in the nanoemulsion were also investigated as well as the
102 need to add a secondary emulsifier to improve the stability of
103 the system. The performances of CAF- or EXM-loaded
104 nanoemulsions and conventional emulsions were compared
105 in terms of the in vitro skin permeation study and retained
106 amounts using modified Franz-type diffusion cell and human
107 epidermis, as a membrane.
108 Materials and methods
109 Materials
110 Each component is used in the study was here reported by
111 using the INCI name in agreement with the conventional no-
112 menclature for cosmetic-grade ingredients. CAF was pur-
113 chased by A.C.E.F. S.p.A. (I). Ethyl Ximenynate (EXM)
114 was supplied by Indena S.p.A. (I). The dicaprylyl ether (DE)
115 and lauryl-glucoside (LG) were purchased by Cognis Italy (I).
116 Ethylhexyl isononanoate (EI) was supplied by Prodotti Gianni
117(I). The commercial mixture of PPG-26-Buteth-26 and
118PEG-40 hydrogenated castor oil was supplied by Res
119Pharma (I). Polysorbate 20 was supplied by Bregaglio (I).
120Phenoxyethanol , methylparaben, buthylparaben,
121ethylparaben, propylparaben and the potassium lauroyl wheat
122amino acid (and) palm glycerides (and) capryloyl glycine
123(NANOCREAM®) were kindly gifted by Sinerga S.p.A. (I).
124All other reagents and solvents were purchased from
125Sigma-Aldrich S.R.L. (I) and used without further
126purification.
127Preparation of viscous yellowish gel-like structure
128The emulsifier (i.e. potassium lauroyl wheat amino acids (and)
129palm glycerides (and) capryloyl glycine) was added in ratio
1301:1 with respect to oil phase (EI 8% w/w; DE 2% w/w).
131Mixtures were maintained in constant stirring by a blade im-
132peller (150–250 rpm) for 10–12 min to obtain a uniform and
133completely homogeneous oil phase (phase A). On the other
134side, water was weighted (phase B). The preservative system
135[i.e. phenoxyethanol, methylparaben, buthylparaben,
136ethylparaben, propylparaben] was also added at 1% w/w.
137After heating both phases at about 70–75 °C, small aliquots
138of phase B were added step by step to phase A under moderate
139stirring. A viscous gel-like structure of yellow colour was
140obtained. The mixture was cooled down to room temperature
141under stirring. When the active ingredients were added, CAF
142were loaded in concentrations of 0.4%w/w and phase B, while
143EXM was 0.8% w/w in phase A. Percentages referred to final
144formulation. CAF or EXM were added before proceeding in
145the preparation of viscous yellowish gel. Percentages referred
146to final formulation.
147Preparation of nanoemulsion
148Phase A and phase B used for the preparation of
149nanoemulsion were made as previously described for viscous
150yellowish gel-like structure. Different ratio of EI and DE were
151used as oil phase as reported in Table 1. The emulsifier [i.e.
152potassium lauroyl wheat amino acids (and) palm glycerides
153(and) capryloyl glycine] was then added in ratio 1:1 with re-
154spect to oil phase. Mixtures were maintained in constant stir-
155ring by a blade impeller (150–250 rpm) for 10–12 min to
156obtain a uniform and completely homogeneous oil phase
157(phase A). On the other side, water was weighted
158(phase B) and preservative system (i.e., phenoxyethanol,
159methylparaben, buthylparaben, ethylparaben, propylparaben)
160was added at 1% w/w. Phase A and an aliquot of phase B
161(about 30% w/w) were, then, heated at 70–75 °C and mixed
162to reach the gel-like structure, then, phase B was further added
163until its concentration reached about 70% w/w. During the
164addition, the mixture colour turned from yellowish to bluish
165Tyndall, indicating the formation of the nanoemulsion (F1–F6,
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166Table 1). Blank nanoemulsion F2 were selected as vehicle to
167load CAF (F7–F10) and EXM (F11–F13). As previously report-
168ed for the gel-like structure, EXM was added in phase A,
169whereas CAF was added in phase B. The nanoemulsions F14
170and F15 were made adding 1.5% w/w of LG to F7, F11, respec-
171tively. Percentages referred to final formulation.
172Preparation of emulsion
173To prepare the conventional emulsion, the emulsifier
174system was prepared mixing Polysorbate 20 (3% w/w)
175to a commercial mixture of PPG-26-buteth-26 and
176PEG-40 hydrogenated castor oil (3% w/w). The ratio
177of EI and DE was fixed at 8:2. The lipophilic compo-
178nents (i.e. EI, DE, emulsifier system) and the preserva-
179tive were heated at 70–75 °C and, then, were added to
180an aqueous solution containing the hydrophilic compo-
181nents (i.e. active ingredients) heated at the same temper-
182ature under vigorously stirring. The preservative system
183(i.e. phenoxyethanol, methylparaben, buthylparaben,
184ethylparaben, propylparaben) was added at 1% w/w.
185The emulsion was cooled down to room temperature
186under continuous stirring. Final ratio water/oil was 70/
18730. 0.8% w/w EXM was added in phase A, whereas
1880.4% w/w CAF was added in phase B. Percentages re-
189ferred to final formulation.
190Nanodroplet dimension measurements
191Measurements of nano-droplet dimension were performed at
19223 °C using a NICOMP380/dynamic light scattering (DLS;
193Particle Sizing System, USA). For each formulation, 1 mL
194was loaded in a cylindric cuvette and directly analysed by
195DLS. For the elaboration of raw scattering signal, 0.933 cP
196of the water viscosity at 23 °C and 1.333 of diffraction index
197were used as parameter.
198Stability study
199The stability of the nanoemulsions at room temperature (RT),
20040 and 50 °C was checked each month over a period of
2013 months by visual inspection, comparing the aspect of
202nanoemulsion with photograph taken at the preparation time.
203In vitro human skin permeation study
204The permeation study was performed bymodified Franz’s cell
205system (self-made apparatus) with a diffusion area of
2060.785 cm2 and a receptor volume of about 6 mL.
207The in vitro permeation and retention studies were per-
208formed using human epidermis (HE) as a membrane. The
209HE originated from the abdominal skin of a single donor
210who underwent cosmetic surgery. Briefly, the full-thickness
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211 skin was sealed in evacuated plastic bags and stored within 6 h
212 after removal, and HE samples were prepared following an
213 internal standard procedure [16]. In particular, the skin was
214 thawed at room temperature, and the excess of fat was care-
215 fully removed. The skin sections were cut into squares of
216 about 4.0 cm2 and after immersion in water at 60 °C for
217 1 min; the HE was gently separated from the remaining tissue
218 with forceps. Then, the HE was frozen at −20 °C until use. All
219 the HE samples used in the in vitro permeation studies were
220 stored in fridge for not more than 1 month.
221 Prior to experiments, HE sample was visually
222 checked to avoid damaged samples. Adequate samples
223 were hydrated in 0.9% w/v NaCl solution for 1 h. Then,
224 the sample was mounted on the Franz diffusion cells,
225 whose receptor compartments were filled with degassed
226 pH 7.4 phosphate buffer saline solution for CAF or with
227 ethanol/water solution (50/50% v/v) for EXM. Special
228 care was given to avoid air bubbles between the buffer
229 and the membrane in the receptor compartment. The
230 upper and lower parts of the Franz cell were sealed
231 with Parafilm® and fastened together by means of a
232 clamp. The system was kept at 37 °C with a circulating
233 water bath, so that the membrane surface temperature
234 was at 32 ± 1 °C throughout the experiment. At the
235 beginning of experiment, 1 mL of nanoemulsion,
236 gel-like structure and emulsion containing either CAF
237 or EXM were loaded in donor compartments. At
238 predetermined times, 200 μL samples were withdrawn
239 from the receiver compartment and analysed in HPLC.
240 The withdrawn aliquot was replaced with the same vol-
241 ume of fresh receiver medium. Sink conditions were
242 maintained throughout the experiments. The results were
243 expressed as the average of parallel experiments per-
244 formed in triplicate. The cumulative amount permeated
245 through the human epidermis per unit area (QP) was
246 calculated from the drug concentration in the receiving
247 medium and plotted as a function of time. The steady
248 state flux (J) was determined as the slope of the linear
249 portion of the plot.
250 Drug retention study
251 At the end of permeation experiment, HE samples were re-
252 moved from the Franz diffusion cells. Any residue on the
253 surface of the skin was removed using a cotton tip applicator
254 and each HE membrane was then carefully rinsed with 5 mL
255 methanol. The skin samples were then cut into small pieces
256 and placed in 10 mL of methanol. The suspension was soni-
257 cated for 30 min, soaked for 24 h at 4 °C, and then filtered.
258 The concentrations of CAF or EXM were assayed by the
259 HPLC method reported below. The retained amount into the
260 human epidermis (QR) was expressed as micrograms per unit
261 of area.
262Quantitative determination of caffeine and ethyl
263ximenynate
264The concentrations of CAF and EXM in the medium were
265determined by a HPLC method (HP 1100, ChemStations,
266Hewlett Packard, USA). The following analytical conditions
267were adopted.
268Caffeine The CAF separation was performed at 25 °C using a
269Spherisorb 3 μm ODS2 (Waters S.p.A., USA) and acetoni-
270trile/0.05 M acetic acid (75:35 v/v) as mobile phase. The flow
271rate was set at 1.0 mL/min and the injection volume at 20 μL.
272The drug concentration was determined at 275 nm from two
273standard curves (0.01–10 μg/mL; 10–100 μg/mL).
274Ethyl ximenynate the EXM separation was performed at 25 °
275C using a Spherisorb 5 μm ODS2 (Waters S.p.A., USA) and
276acetonitrile/water acidified with 0.3% phosphoric acid 85%
277(90:10) as mobile phase. The flow rate was set at 1.2 mL/
278min and the injection volume at 10 μL. The drug concentra-
279tion was determined at 215 nm from two standard curves
280(0.01–10 μg/mL; 10–100 μg/mL).
281Statistical analysis
282Dixon’s tests were performed on the obtained results to iden-
283tify outliners, using a value of 0.970 as confidence level at
28490% [17]. The statistical difference in performances of the
285formulations samples were at each sampling point by T test
286(Excel 2016, Microsoft, USA). The level of significance was
287taken as p < 0.05.
288Results
289Preparation and stability of nanoemulsions and gel-like
290structure
291O/W nanoemulsions containing ethylhexyl isononanoate (EI)
292and dicaprylyl ether (DE), as oily phase, and a blend of natural
293derived surfactants, potassium lauroyl wheat amino acids,
294palm glycerides and capryloyl glycine (Nanocream®), as
295nanoemulsifier were prepared [18]. The emulsifier appears
296like a semi-consistent yellow gel, with a characteristic odour
297and pH value between 6.5 and 7.5; it is a non-irritant blend and
298it is compatible with oils having a branched-structure on the
299carbonic chain and a limited steric volume (e.g. iso-stearate,
300ethyl isononanoate or iso-hexadecane). The ratio oil phase/
301nanoemulsifier was set 1:1 w/w, according to previous evi-
302dences [15]. Rheological measurements (data not shown)
303demonstrated that oil phase/nanoemulsifier system could in-
304corporate low amounts of water (<25–30%) without altering
305its gel-like structure. DLS analyses did not evidence any
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306 droplet formation inside this structure. On the contrary, a fluid
307 O/W nanoemulsion was obtained when the water concentra-
308 tion reaches 70% (w/w), regardless of the oil phase
309 composition.
310 All prepared blank nanoemulsions had a low viscosity as
311 they easily flowed (data not shown). They appeared clear or
312 opalescent after preparation (Table 1), and DLS analyses con-
313 firmed that droplet dimensions ranged from 30 to 50 nm. The
314 higher DE concentration increased, the higher clearness of
315 system.
316 The stability studies demonstrated that almost all blank
317 formulations (F1–F6) remained stable over 3 months both at
318 RT and at 40 °C, whereas phase separation (e.g. creaming)
319 was observed at 50 °C (Table 1). The visual aspect of some
320 formulations proceeded from the clearness towards the opal-
321 escence to reach, in case of instability, the whitening and then
322 creaming, but it could also happen that from an opaque system
323 they went back to a transparent one. According to the stability
324 data reported in Table 1, best results were obtained with the
325 ratio EI/DE fixed at 8/2, 4/6 and 2/8.
326 The addition of CAF or EXM significantly affected the
327 physical properties and the stability of all the nanoemulsions
328 (Table 1, Table A1). When different concentrations of CAF
329 and EXM were added to the formula, at high temperature
330 nanoemulsions made with the EI/DE 2/8 and 4/6 resulted
331 unstable within 1 month after the preparation (Table A1). On
332 the contrary, when EI/DE was fixed at 8/2, the nanoemulsions
333 containing 0.4% w/w CAF (F7) were clear and stable for a
334 longer period, whereas the higher CAF concentration (i.e.
335 0.8–2.0% w/w, F8–F10) resulted quickly unstable at elevated
336 temperatures (Table 1). The DLS analyses highlighted signif-
337 icant variation in droplet dimension: if droplet dimension of
338 0.8% w/w CAF nanoemulsion (i.e. 38 nm) resulted superim-
339 posable to blank formulation immediately after preparation,
340 after 3 months at room temperature three different droplet
341 populations were observable (range: 12–601 nm). Such find-
342 ings were confirmed by visual observation: instability ap-
343 peared as a separation phase characterized by a white cream
344 at the top of the sample, while at the bottom the system
345remained transparent. On the contrary, the samples containing
3460.8% (F11) and 1.4% (F12)w/w EXMwere homogeneous for a
347longer period of time with respect to those with CAF, even if
348DLS analyses highlighted the presence of a 338-nm popula-
349tion of droplets. A 2% w/w EXM (F13) formulation resulted
350unstable also at RT. Differences were observed at 50 °C; sep-
351aration phase was observed after 1 month in the case of 1.4%
352w/w. Therefore, to improve the stability of formulations F7 and
353F11, LG, a non-ionic mild surfactant, was added. A mixture of
354lauryl glucoside and sodium lauryl glucose carboxylate com-
355bined to a polymeric stabilizer is commonly used in emulsion
356formulations to improve stability [19].
357All gel-like structures were stable at each condition of time
358and temperature, except for CAF 0.8w/w. In this case, at room
359temperature the active precipitated as needle-like particles,
360due to achievement of the solubility limit.
361In vitro permeation studies
362In vitro permeation studies were carried out comparing per-
363formances of nanoemulsions F14 and F15 (Table 1) with those
364of emulsions and gel-like structures containing CAF (0.4%,w/
365w) or EXM (0.8%, w/w). As shown in Table 2, both model
366drugs were able to penetrate significantly the stratum corneum
367and to permeate through the human epidermis. However, the
368permeated and retained percentage were lower than 2% of
369both CAF and EXM in the case of nanoemulsions. The per-
370meation profiles of EXM-loaded emulsion resulted negligible,
371whereas those obtained by nanoemulsion were significantly
372higher after 24 h (p value <0.05). On the other side, the results
373obtained by using the CAF-loaded emulsion was comparable
374to that of the nanoemulsion F14. QR were not statistically dif-
375ferent (p value >0.05).
376The gel-like structures permitted to increase QP indepen-
377dently of the considered model drug. Indeed, the QP,24 value
378for CAF was 12.6 ± 7.2% of drug loading. It was over ten
379times higher than those of nanoemulsion and coarse emulsion
380(p value <0.05), whereas the QR values were only slightly
t2:1 Table 2 Permeation and
retention parameters obtained by
in vitro permeation studies carried
out using nanoemulsions (F14,
F15), emulsions and gel-like
structures containing CAF (0.4%
w/w) or EXM (0.8% w/w)
t2:2 Formulation QP,24
(μg/cm2)
J
(μg/cm2/h)
QR
(μg/cm2)
t2:3 Caffeine
t2:4 Nanoemulsion (F14) 47.02 ± 28.91 (0.5%) 2.44 ± 1.53 84.18 ± 32.01 (0.8%)
t2:5 Emulsion 36.05 ± 10.75 (0.3%) 1.74 ± 0.58 145.71 ± 102.98 (1.3%)
t2:6 Gel-like structure 777.25 ± 290.40 (12.6%)* 42.60 ± 22.61* 242.37 ± 82.24 (2.2%)
t2:7 Ethyl ximenynate
t2:8 Nanoemulsion (F15) 19.88 ± 13.07* 0.51 ± 0.11 139.29 ± 87.57 (1.1%)
t2:9 Emulsion 0.00 ± 0.00 0.00 ± 0.00 63.66 ± 33.40 (0.6%)
t2:10 Gel-like structure 41.13 ± 22.28* 1.62 ± 1.05 54.82 ± 29.01 (0.8%)
*p value <0.05 with respect to control (i.e. emulsion)
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381 increased. For EXM, QP,24 value was 4.1 ± 1.3% of drug
382 loading.
383 Discussion
384 The current manuscript showed whether and to what extent
385 the permeation profiles of CAF or EXM were modified when
386 loaded in nanoemulsions. The performance of nanoemulsions
387 in terms of permeation profile of CAF or EXM were tested
388 using as reference a coarse emulsion. Moreover, the impact on
389 permeation profiles of the different organization of the
390 semi-solid structure due to a reduced water phase was also
391 evaluated using the viscous gel-like structures. As shown in
392 Table 1 and Table 2, the loading of CAF or EXM in this
393 nanoemulsion system has significantly modified its stability
394 and permeation parameters of the actives, but the enhance-
395 ment effect of nanoemulsion in comparison to coarse emul-
396 sion varies according to the polarity of the tested molecule.
397 Based on the results obtained by using CAF, the perme-
398 ation and retention pattern of polar molecules seemed to not
399 vary between nano- or conventional emulsions (Fig. 1a). The
400obtained permeation fluxes (J) also resulted in agreement with
401previously published data obtained with CAF aqueous solu-
402tions [20], suggesting that both formulations did not alter the
403CAF permeation profile. On the contrary, the J value was
404significantly increased when viscous gel-like structure was
405used as vehicle (Table 2). Considering the lower water con-
406centration of this formulation with respect to the
407nanoemulsion (i.e. 30 vs 70%), such enhancement effect
408may be caused by the higher thermodynamic activity of
409CAF inside the gel-like structure [21]; higher occlusive prop-
410erties could also influence this result [22]. The closeness to
411maximum solubility of CAF is evidenced by preliminary sta-
412bility studies. Indeed, in CAF-loaded gel-like structures the
413drug crystal precipitation occurred when its concentration ap-
414proaches 0.8%w/w, while no CAF precipitation was observed
415in the case of nanoemulsion till 2% w/w.
416When nanoemulsion was loaded with an apolar molecule
417(e.g. EXM), a significant enhancement effect on the perme-
418ation profile is observable (Fig. 1b). While the permeation
419profile of EXMwas negligible for the conventional emulsion,
420the nanoemulsion and gel-like structure resulted in compara-
421ble QP- and J values. Between the two formulations, no
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Fig. 1 In vitro permeation
studies of CAF (a) and EXM (b)
through human epidermis using
different semisolid vehicles (CAF
0.4% w/w; EXM 0.8% w/w). The
results showed the impact of
vehicle selection on the
permeation profiles both active
ingredients. The selected
semisolid vehicles are emulsion
(solid line), gel-like structure
(dashed line) and nanoemulsions
profile (dotted line) (mean ± St.
dev.; n = 3)
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422 significant differences in terms of permeation parameters were
423 observed, despite LG was added only in the nanoemulsion.
424 The addition of LG, a secondary emulsifying agent, was need-
425 ed for obtaining an acceptable stability of nanoemulsion dur-
426 ing times, especially when CAF and EXM were loaded. LG
427 was selected with respect to previous experiences as
428 nanoemulsion stabilizer, being quite common this need.
429 Even if release from an emulsion and human skin permeability
430 of active ingredients could be affected by the type of emulsi-
431 fier [23], in this case, it is possible to exclude that the addition
432 of a further emulsifier system plays a role in promoting the
433 permeation of CAF or EXM through the skin.
434 Unlike CAF, these findings suggested that it is possible to
435 improve the permeation profiles of apolar active ingredient,
436 using nanoemulsion as vehicle. Moreover, due to the different
437 O/W ratio, the EXM release was more efficient in the presence
438 of the highest amount of water, even if permeation parameters
439 were not significantly altered.
440 The overall results agreed with previous published studies
441 that demonstrated that nanoemulsions could improve the per-
442 meation profiles of loaded active ingredients [24–26]. The
443 different performance of nanoemulsion in comparison to a
444 coarse emulsion can be explained considering that the inter-
445 face between oil and aqueous phase resulted increased in the
446 case of O/W nanoemulsion with respect to the equivalent
447 emulsion. The higher interface area between the two phases,
448 the higher proximity between the droplets of the disperse
449 phase and the skin surface after a topical application. In this
450 context, the different in vitro permeation profile observed for
451 apolar molecules with respect to polar one may be explained
452 with a higher partition tendency of the formers between the
453 vehicle and the skin surface due to the increased concentration
454 at the skin-vehicle interface.
455 Such evidences suggested that the safety profiles of
456 nanoemulsion cannot be considered a priori superimposable
457 to coarse emulsion with similar composition of phases, espe-
458 cially when molecules with physicochemical properties
459 favourable for the skin permeation were loaded.
460 On the bases of such considerations, a revision of regulatory
461 framework of nanoemulsion to preserve the costumer safety ap-
462 pears necessary in consideration of the widespread diffusion of
463 such nanomaterials in cosmetic products. Nanoemulsions are not
464 classified as nanomaterials by European authorities [11] and their
465 risk assessment is mainly based on the safety profile of all the
466 ingredients contained in the cosmetic product. Indeed, since
467 nanoemulsions are equally based on the well-known and
468 well-characterized raw materials used for conventional emul-
469 sions, they are not considered risky for the safety of European
470 consumers. Nevertheless, even if the composition of a
471 nanoemulsion is similar to coarse emulsion and with safety in-
472 gredients, the reduced droplet dimensions or modification in the
473 emulsifier systems for preserving the formulation stability have
474 to be considered as function of their impact on the safety profile
475of the formulation. Therefore, novel approach proposed by FDA
476to solve the criticisms results of interest. FDA classifies
477nanoemulsions as nanomaterials [10] and recommends to con-
478duct a deepened characterization of both ingredients and final
479formulation as a function of the intended route of exposure
480[27]. For exposure via dermal absorption, since nanoemulsions
481are expected to disintegrate in their molecular components upon
482the application to skin, their safety assessment is not considered
483particularly critical by the American authorities again. However,
484FDA highlights the importance to conduct proper in vitro studies
485through intact and impaired skin to verify that permeation rate of
486ingredients is not enhanced by the nanoemulsion, excluding thus
487a high risk of systemic exposure after skin application.
488Conclusions
489The overall results demonstrated that nanoemulsions are able to
490influence significantly the permeation profiles of molecules as a
491function of their physicochemical properties. In particular, O/W
492nanoemulsions can improve significantly the permeation profiles
493of apolar active ingredients in comparison to conventional emul-
494sions, whereas no differences were observable for polar mole-
495cules. Considering such findings, it is worth observing that there
496is room for reconsidering the regulatory framework on the basis
497of the risk assessment of nanoemulsion-based cosmetic products.
498Indeed, according to our results, the lack of the skin permeability
499evaluation in the current European legislation seems appropriate
500for assessing the safety of O/W nanoemulsions containing active
501polar ingredients, since their use for improving the physical prop-
502erties of final products does not influence the skin permeation
503pattern of ingredients. On the other hand, the loading of apolar
504active ingredients in O/W nanoemulsions should be carefully
505considered to avoid any unexpected increase of exposure to ac-
506tive ingredients and, therefore, potential risks for the consumer
507safety. Therefore, an upgrade and harmonization of the regulato-
508ry framework is desirable to assess better how the use of a nano-
509scale emulsion instead conventional one can impact on the con-
510sumer exposure to ingredients contained in cosmetic products
511intended to be commercialized in both Europe and the USA.
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